ARCHIVES

President’s Budget Request for FDA Omits Funding for Critical Path.

This article is from The Cancer Letter archive.

Vol. 34 No. 05 | February 8, 2008

Download PDF Visit The Full Archive

Related Articles

Anna Barker Named Deputy Director for Strategic Scientific Initiatives

December 6, 2002

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

March 28, 2014

New Drug for Lymphoma Enters Phase II Trial

May 28, 2004

Biotheraputices To Reveal Plans for Expansion

August 8, 1986

Melanoma Cancer Vaccine Tested By Cooperative Group

August 29, 2003

In Brief: FDA approves Three-Hour Taxol Infusion; Foti Elected President Of NCCR; Luce Retires

September 9, 1994